How I Treat Paroxysmal Nocturnal Hemoglobinuria (PNH)
| Overview / Abstract: |
In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment response is suboptimal? View the activity and find out! |
|
Expiration |
Jun 30, 2024 |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.0 |
|
Accreditation |
ACCME, ACPE, CBRN |
|
Presenters / Authors / Faculty |
Jamile M. Shammo, MD, FASCP, FACP Carlos de Castro, MD |
|
Sponsors / Supporters / Grant Providers |
This educational activity is presented in collaboration with Rush University Medical Center and Academy for Continued Healthcare Learning (ACHL). Supported by educational grants from Alexion Pharmaceuticals and Apellis Pharmaceuticals, Inc |
|
Keywords / Search Terms |
ACHL CME, Paroxysmal nocturnal hemoglobinuria, PNH, C5 inhibitor, eculizumab, ravulizumab, C3 inhibitor, pegcetacoplan, hemolysis, thrombosis, complement inhibitors, anemia, transfusion, breakthrough hemolysis, QoL, quality of life Free CE CME |
|